Virtual Library

 x 
My Library Virtual Library FAQ

Start Your Search

Chan Kwon Park



Author of

  • +

    P1.01 - Advanced NSCLC (ID 757)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P1.01-076 - Comparison of PANA Mutyper and PNA Clamping for Detecting KRAS Mutations in Tumor Tissue, Cell Block and Pleural Effusion from Cancer (ID 9920)

      09:30 - 09:30  |  Presenting Author(s): Chan Kwon Park

      • Abstract

      Background:
      Recently, target therapy for cancer patients should be considered according to the individual mutational status. Therefore, detection of mutations is clinically important for patients’ outcome. Molecular testing of lung cancer is one of the most important standard of care and treatment. However, it is not always easy to get enough tumor tissue from patients. There is a promising novel mutation detection technology, which is PANA Mutyper. We compared effectiveness of both methods for the detection of KRAS mutation using tumor tissues, cell blocks and pleural effusions with patients with malignant pleural effusion.

      Method:
      : KRAS mutations were assessed by PANA Mutyper and PNA clamping using tumor tissues, cell blocks and pleural effusions. The diagnostic usefulness of two methods were analyzed.

      Result:
      A total of 104 patients with malignant pleural effusion were enrolled which includes 56 adenocarcinoma of lung, 11 squamous carcinoma of lung, 17 small cell lung cancer, 3 large cell lung cancer, 3 stomach cancer, 2 ovary cancer, etc. PANA Mutyper showed more superior detection rate than PNA clamping through tumor tissues, cell blocks and pleural effusions.

      Conclusion:
      PANA Mutyper had a diagnostic superiority for the detection of KRAS mutations in patients with malignant pleural effusion. This method can be used as more sensitive and accurate detection of KRAS mutations. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A1A11052422).

  • +

    P1.03 - Chemotherapy/Targeted Therapy (ID 689)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Chemotherapy/Targeted Therapy
    • Presentations: 1
    • +

      P1.03-025 - Combination Therapy with Carboplatin and Hyperoxia Synergistically Enhances Suppression of Benzo[a]Pyrene Induced Lung Cancer (ID 8432)

      09:30 - 09:30  |  Author(s): Chan Kwon Park

      • Abstract
      • Slides

      Background:
      We explored the effects of intermittent normobaric hyperoxia alone or combined with chemotherapy on the growth, general morphology, oxidative stress, and apoptosis of benzo[a]pyrene (B[a]P)-induced lung tumors in mice.

      Method:
      Female A/J mice were given a single dose of B[a]P and randomized into four groups: (1) control, (2) carboplatin (50 mg/kg intraperitoneally), (3) hyperoxia (95% fraction of inspired oxygen), and (4) carboplatin and hyperoxia. Normobaric hyperoxia (95%) was applied for 3 h each day from weeks 21 to 28. Tumor load was determined as the average total tumor numbers and volumes. Several markers of oxidative stress and apoptosis were evaluated.

      Result:
      Intermittent normobaric hyperoxia combined with chemotherapy reduced the tumor number by 59% and the load by 72% compared with the control B[a]P group. Intermittent normobaric hyperoxia, either alone or combined with chemotherapy, decreased the levels of superoxide dismutase (SOD) and glutathione (GSH) and increased the levels of catalase and 8-hydroxydeoxyguanosine (8-OHdG). The Bax/Bcl-2 mRNA ratio, caspase-3 level, and number of transferase-mediated dUTP nick end-labeling (TUNEL)-positive cells increased following treatment with hyperoxia with or without chemotherapy.

      Conclusion:
      Intermittent normobaric hyperoxia was found to be tumoricidal and thus may serve as an adjuvant therapy for lung cancer. Oxidative stress and its effects on DNA are increased following exposure to hyperoxia and even more with chemotherapy, and this may lead to apoptosis of lung tumors.

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

  • +

    P3.01 - Advanced NSCLC (ID 621)

    • Event: WCLC 2017
    • Type: Poster Session with Presenters Present
    • Track: Advanced NSCLC
    • Presentations: 1
    • +

      P3.01-057 - Comparison of EGFR Mutations in Matched Tumor Tissues, Cell Blocks, Pleural Effusions and Bloods with NSCLC, by PANA Mutyper and PNA Clamping (ID 9829)

      09:30 - 09:30  |  Author(s): Chan Kwon Park

      • Abstract

      Background:
      There has been a marvelous paradigm shift in the diagnosis and management of lung cancer, with the discovery of driver mutations that can be targeted by specific inhibitors. Personalized therapy is driving the demand for mutation testing in cancer. Especially, molecular testing of lung adenocarcinoma for the epidermal growth factor receptor (EGFR) is now considered one of the most important standard of care with other driver mutations. However, sampling tumor tissue other than surgical resection has inevitable limitations. It may be difficult to obtain enough DNA for EGFR mutation test if biopsy tissue was inadequate. There is a promising ctDNA detection technology, that is PANA Mutyper technology, which is a novel technology that integrates PNA clamp and PANA S-melting. We investigated effectiveness of both methods for the detection of EGFR mutation.

      Method:
      Ninety patients with malignant pleural effusion of lung cancer were enrolled. EGFR mutations were assessed by PANA Mutyper and PNA clamping using tumor tissues, cell blocks, pleural effusions, and bloods separated by serum and plasma. The diagnostic performance of both methods was investigated.

      Result:
      Among the 90 patients with malignant pleural effusion of lung cancer, 56 patients were adenocarcinoma of lung, 11 were squamous carcinoma of lung, and 17 were small cell lung cancer. PANA Mutyper using bloods showed that 70% sensitivity, 100% specificity, 100% positive predictive value and 83% negative predictive value comparing to the combination of PANA Mutyper and PNA clamping through tumor tissues, cell blocks and pleural effusions (p=0.014).

      Conclusion:
      PANA Mutyper using bloods had a diagnostic performance for the detection of EGFR mutations in NSCLC that was comparable to that of tumor tissues, cell blocks and pleural effusions. The diagnostic performance of PANA Mutyper was better than that of PNA clamping. This work was supported by the National Research Foundation of Korea (NRF) grant funded by the Korea government (MSIP) (No. 2014R1A2A1A11052422).